Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRoyalty Pharma Plc

Royalty Pharma Plc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
68.38 USD -0.39 ( 0.57%)
Last update at 2026-11-10T15:03:00Z
VOLUME
215715
Market Cap
33786.04M
P/E
31.78

Momentum Score

…

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
68.19
Low
68.86
High
52 Week Price Range
33.97
Low
64.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
68.77
Dividend Yield
1.54%
Revenue TTM
2536.00M
Revenue Per Share
5.82
Gross Profit TTM
2430.03M
Debt / Equity
1.38
ROE
13.97%
Net Debt
8332.22M
ROCE
8.60%
Diluted EPS TTM
1.84

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1324.19M 1330.81M 1700.09M 230.06M 1241.20M
Minority interest -553.25M -471.83M -565.25M 187.23M 621.47M
Net income 770.95M 858.98M 1134.83M 42.83M 478.75M
Selling general administrative 573.48M 236.67M 249.75M 227.30M 182.83M
Gross profit 2378.19M 2263.58M 2354.55M 2231.55M 2266.47M
Reconciled depreciation 3.85M 0.00M 0.00M 5.67M 23.00M
Ebit 1631.86M 1292.44M 1492.15M 977.50M 1430.71M
Ebitda 1635.71M 1556.33M 1887.28M 983.17M 1482.08M
Depreciation and amortization 3.85M 1272.56M 5.67M 5.67M 51.36M
Non operating income net other - - - 110.96M -23.37M
Operating income 1559.52M 1292.44M 1492.15M 977.50M 1430.71M
Other operating expenses 818.67M 971.13M 862.40M 1314.32M 858.75M
Interest expense 307.66M 225.51M 187.19M 187.96M 166.14M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 33.59M 47.34M 72.29M 78.33M 53.53M
Net interest income -274.07M -178.17M -114.90M -109.63M -112.61M
Non recurring - - - 1520.07M -
Income tax expense 553.25M 472.00M 565.25M 187.23M 762.45M
Total revenue 2378.19M 2263.58M 2354.55M 2237.22M 2289.46M
Total operating expenses 818.67M 971.13M 862.40M 1314.32M 858.75M
Cost of revenue 3.85M 732.46M 560.66M 5.67M 23.00M
Total other income expense net -235.33M 38.37M 207.94M -747.43M -189.51M
Net income from continuing ops 1324.19M 1330.81M 1700.09M 230.06M 1241.20M
Net income applicable to common shares - - - 42.83M 619.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19620.78M 18222.72M 16381.85M 16813.47M 17515.87M
Intangible assets - 15127.16M 1.78M - 5.67M
Other current assets -902.20M 4.19M 3.80M 90.52M 6.63M
Total liab 9905.84M 7880.35M 6297.56M 7288.09M 7267.32M
Total stockholder equity 6476.90M 6946.58M 6526.50M 5628.15M 5776.59M
Other current liab 236.81M 242.47M 146.21M 161.37M 165.63M
Common stock 0.11M 0.11M 0.04M 0.11M 0.11M
Capital stock 0.11M 0.11M 0.11M 0.11M 0.11M
Retained earnings 2356.32M 2845.65M 2517.58M 1964.69M 2255.18M
Other liab - - - 2.50M -
Good will 924.63M 0.00M - - -
Other assets 1939.00M - - 13508.24M 13722.39M
Cash 618.70M 929.03M 477.01M 1710.75M 1541.05M
Total current liabilities 636.21M 1253.62M 161.38M 1166.78M 171.25M
Net debt 8332.22M 6683.40M 5658.27M 5405.57M 5555.02M
Short term debt 380.00M 997.77M - 997.51M -6891.67M
Short long term debt 380.00M 997.77M - 997.51M -
Short long term debt total 8950.92M 7612.43M 6135.28M 7116.32M 7096.07M
Other stockholder equity 4120.48M 4100.82M 4008.81M 3663.35M 3504.82M
Total current assets 619.00M 1802.14M 1274.19M 2554.91M 2878.21M
Long term investments 17088.76M 16387.04M 15101.14M 14116.58M 14358.04M
Net tangible assets - - - 5628.15M 5770.92M
Short term investments 18.80M 841.97M 18.30M 717.04M 1262.22M
Net receivables 883.70M 26.96M 775.09M 36.60M 68.31M
Long term debt 8570.92M 6614.65M 6135.28M 6118.81M 7096.07M
Accounts payable 19.40M 13.37M 15.16M 7.91M 5.62M
Noncontrolling interest in consolidated entity - - - 3897.22M 4471.95M
Accumulated other comprehensive income - - 0.06M - 16.49M
Common stock total equity - - - 0.11M 0.11M
Retained earnings total equity - - - 1964.69M 2255.18M
Treasury stock - - - -2.81M -2.71M
Non currrent assets other 15967.05M -15093.62M 14093.40M 29.63M 4.14M
Non current assets total 17063.00M 16420.58M 15107.66M 14258.56M 14637.65M
Long term debt total - - - 6118.81M 7096.07M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1364.65M -2678.11M -657.88M -1152.79M -1832.50M
Change to liabilities - - - 2.29M -4.59M
Total cashflows from investing activities -1614.18M -2678.11M -2072.79M -1029.42M -1870.28M
Net borrowings 954.48M 1471.23M -1000.00M -1.35M 1259.49M
Total cash from financing activities -1185.97M 361.14M -2148.75M -944.86M 385.11M
Change to operating activities - - - -6.08M 8.39M
Net income 1324.19M 1330.81M 1700.09M 230.06M 1241.20M
Change in cash -310.33M 452.02M -1233.74M 169.70M 532.37M
Begin period cash flow 929.03M 477.01M 1710.75M 1541.05M 1008.68M
End period cash flow 618.70M 929.03M 477.01M 1710.75M 1541.05M
Total cash from operating activities 2489.82M 2768.99M 2987.80M 2143.98M 2017.54M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 3.85M 0.00M 20.50M 5.67M 23.00M
Other cashflows from investing activities -175.11M -49.32M 29.44M 123.37M -37.78M
Dividends paid 378.25M 376.46M 358.33M -333.32M -285.18M
Change to account receivables -2.36M -4.55M -1.52M 2543.69M 2295.72M
Sale purchase of stock -1227.38M -229.65M -304.76M -144.12M -479.60M
Other cashflows from financing activities -534.81M -503.97M -485.67M -611.53M 670.30M
Change to netincome - - - 64.12M 37.52M
Capital expenditures 0.00M 0.00M 2115.52M 2041.15M 0.52M
Cash flows other operating - - - 2079.86M 1980.02M
Cash and cash equivalents changes - - - 169.70M 532.37M
Change in working capital -17.15M 53.38M 5.38M 32.66M -16.32M
Stock based compensation 289.89M 2.34M 2.36M 2.17M 2.44M
Other non cash items 889.04M 1382.45M 1279.97M 1873.41M 2289.58M
Free cash flow 2489.82M 2768.99M 2987.80M 4185.13M 2018.06M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RPRX
Royalty Pharma Plc		 -0.39
0.57%		 68.38 31.78 30.12 13.32 3.85 13.22 19.57
NVO
Novo Nordisk A/S		 -0.70
1.70%		 40.67 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.79
0.14%		 550.08 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -6.17
0.67%		 913.79 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Royalty Pharma Plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

110 East 59th Street, New York, NY, United States, 10022

212 883 0200

https://www.royaltypharma.com

100

Name Title Year Born
Mr. Pablo Gerardo Legorreta Founder, Chairman & CEO 1964
Mr. Terrance P. Coyne Exec. VP & CFO NA
Mr. George Wingate Lloyd Exec. VP of Investments & Chief Legal Officer 1959
Mr. Christopher Hite Vice Chairman & Exec. VP 1967
Dr. Marshall Urist M.D., Ph.D. Exec. VP and Head of Research & Investments NA
Mr. Arthur R. McGivern J.D. Exec. VP of Investments & Gen. Counsel NA
Ms. Kristin Stafford Sr. VP & Chief Accounting Officer NA
Dr. James Folmar Reddoch Ph.D. Exec. VP of Investments & Chief Scientific Officer 1970
Mr. George Grofik C.F.A., CPA Sr. VP and Head of Investor Relations & Communications NA
Ms. Alessandra Sassun VP & Head of Human Capital NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

No data available
No data available

Equity Sectors*

  • Basic Materials

    -2.54%

  • Communication Services

    +0.09%

  • Consumer Cyclical

    -0.16%

  • Consumer Defensive

    -0.14%

  • Energy

    -1.11%

  • Financial Services

    +0.15%

  • Healthcare

    -0.77%

  • Industrials

    -0.93%

  • Real Estate

    -0.17%

  • Technology

    -0.09%

  • Utilities

    -0.67%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…